2016 American Transplant Congress
Everolimus versus Mycophenolate Mofetil in Combination with Tacrolimus: A Propensity Score Matching Analysis in Liver Transplantation.
Background: No trial has so far investigated everolimus (EVR)-incorporating immunosuppressive regimens versus combined use of tacrolimus (TAC) and mycophenolate mofetil (MMF) in liver transplantation (LT).Materials…2016 American Transplant Congress
Pre-Transplant IgM to Post-Transplant IgG DSA Conversion May Be Affected by Immunosuppression.
1Terasaki Foundation Laboratory, Los Angeles, CA; 2East Carolina University, Greenville, NC.
Post-transplant (tx) IgG donor-specific antibodies (DSA), but not IgM DSA has been identified as one of the major causes of late graft loss. Considering the…2016 American Transplant Congress
Long-Term Outcomes of ATG versus IL-2 Receptor Antagonist in Low Risk Kidney Transplant Recipients: Donor Factors.
Controversy exists regarding the optimal choice of induction therapy in low-risk kidney transplant (KT) recipients. Current guidelines specify induction choices in KT based on recipient…2016 American Transplant Congress
Everolimus (EVR) versus Mycophenolate Sodium (MPS) for Recipients of Kidney Transplants from Expanded Criteria Donors (ECD) Receiving Anti-Thymocyte Globulin (r-ATG) and Tacrolimus (TAC).
Introduction: There is no standard of care immunosuppressive regimen for recipients of kidneys recovered from expanded criteria donors. Several centers use r-ATG induction due to…2016 American Transplant Congress
Earlier Repletion of Lymphocytes After Alemtuzumab Induction Is Associated with a Lower Incidence of Infection Following Renal Transplantation.
Imperial College Renal and Transplant Centre, Hammersmith Hospital, London, United Kingdom.
Introduction: Alemtuzumab has been increasingly used as an induction agent in renal transplantation, although the optimal dose is unknown. We have previously reported that alemtuzumab…2016 American Transplant Congress
Induction Therapy with Rabbit Antithymocyte Globulin (rATG, Thymoglobulin®) vs Basiliximab After Kidney Transplantation: A Health Economic Analysis from a German Perspective.
Study objective. A health economic analysis was undertaken to quantify the economic consequences of acute rejection and serious adverse events in patients receiving induction with…2016 American Transplant Congress
Evaluation of a Risk-Stratified Induction Immunosuppression Protocol Utilizing Low-Dose Antithymocyte Globulin in Renal Transplantation.
Lower doses of rabbit-derived antithymocyte globulin (rATG) may result in less infection and cost, but may increase the incidence of acute rejection. We compared the…2016 American Transplant Congress
B Cell Signature Profiling in Kidney Transplant Patients on Thymoglobulin.
Purpose: B cell subsets could be used as biomarkers to modulate therapy regimens in kidney transplant patients. B cell subsets occur with varying proportions within…2016 American Transplant Congress
Denosumab Prevents Bone Mineral Density Loss in De Novo Kidney Transplant Recipients: Results from a Randomized Controlled Trial.
Background: Kidney transplantation is associated with bone loss and an increased risk of fracture. Since current therapeutic options to prevent bone loss are limited we…2016 American Transplant Congress
Treatments Against Renin-Angiotensin-Aldosterone System Could Influence FGF23 and Klotho Levels in Renal Transplant Recipients.
Purpose: Angiotensin-converting enzyme inhibitor ( ACEI) and angiotensin II receptor blocker (ARB) are frequently used in post transplant hypertension. Recent trials reported that renin-angiotensin-aldosterone system…
American Transplant Congress abstracts